Neurolixis launched a collaboration with the GALA^® laboratory in Castres, France. GALA^® is a platform of the Rapsodee/IMT Mines Albi research facility and has experimental tools and skills across a wide range of drug formulation technologies.

The Neurolixis-GALA collaboration focuses on the development of a novel formulation of NLX-112. This compound is in clinical development for treatment of dyskinesia (abnormal movements) seen in patients suffering from Parkinson's disease and the new formulation will optimize its therapeutic activity and facilitate its administration to patients. The development of NLX-112 has been supported by grants from the Michael J. Fox Foundation (USA) and Parkinson's UK. The Neurolixis-GALA collaboration is financed by subsidies from the Occitanie Region in France.

Adrian Newman-Tancredi, PhD, DSc, Chief Scientific Officer of Neurolixis, commented: "The development of a novel formulation of NLX-112 will be strong asset for the project and enable Parkinson’s disease patients (about 1 million in the USA) to maximally benefit from this innovative treatment.”